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Abstract  
Significance: Ionising radiation can induce a wide range of unique DNA 
lesions due to the spatio-temporal correlation of the ionisation produced. Of 
these DNA DSB play a key role. Complex mechanisms and sophisticated 
pathways are available within cells to restore the integrity and sequence of the 
damaged DNA molecules.  
Recent Advances:  Here, we review the main aspects of the DNA DSB repair 
mechanisms with emphasis on the molecular pathways, radiation induced 
lesions and their significance for cellular processes. 
Critical Issues: Although the main characteristics and proteins involved in the 
two DNA DSB repair processes present in eukaryotic cells (homologous 
recombination and non-homologous end joining) are reasonably well 
established, there are still uncertainties regarding the primary sensing event 
and their dependency on the complexity, location and time of the damage. 
Interactions and overlaps between the different pathways play a critical role in 
defining the repair efficiency and determining the cellular functional behaviour 
due to unrepaired/miss-repaired DNA lesions. The repair pathways involved in 
repairing lesions induced by soluble factors released from directly irradiated 
cells may also differ from the established response mechanisms.  
Future Directions: An improved understanding of the molecular pathways 
involved in sensing and repairing damaged DNA molecules and the role of 
DSB is crucial for the development of novel classes of drugs to treat human 
diseases and to exploit characteristics of ionising radiation and alterations in 
tumour cells for successful radiotherapy applications.  
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Innovation 
DNA double-strand breaks, where both strands of the double helix are broken 
are potentially very harmful to cells. Ionising radiations are very effective at 
producing DSB alongside other DNA lesions and cells have evolved pathways 
to try and remove these lesions. These detect the presence of damage then 
activate different repair pathways. Oxygen dependent reactive free radicals can 
also lead to DSB during DNA synthesis. Cells can also communicate between 
each other by bystander signals which can lead to indirect DSB. These 
pathways are being exploited to improve the efficiency of radiotherapy in 
combination with DSB repair inhibitors.  
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1. Introduction to radiation-induced DNA damage and repair 
 
All cells have extensive DNA repair mechanisms, which have evolved to 
maintain the stability of their genomes. This includes dealing with the 
consequences of DNA damage either from endogenous or exogenous sources. 
A careful balance must be maintained between the effective repair of DNA 
damage leading to genetic stability and survival, as the consequence of 
defective or incomplete repair can be genetic instability, which may lead to 
genetic divergences or disease such as cancer and other hereditary disease 
(96). Much of the endogenous DNA damage comes from reactive oxygen 
species produced during normal oxidative metabolism, which leads to 
increased levels of oxidised base damage (70).  Estimates of endogenous 
damage as high as 10,000 DNA damages per cell per day (72) have been 
reported although there are significant uncertainties over the measurements of 
these with recent work suggesting specific lesions are at much lower levels 
(42). Replication errors can also occur, leading to either the wrong or a 
modified base being incorporated. Finally, cells can be exposed to a range of 
exogenous environmental sources of DNA damage including ionising radiation 
(IR), ultraviolet (UV) radiation and multiple types of different chemicals, such as 
inhibitors of topoisomerase II and the radiomimetic agent bleomycin. Of these, 
ionising radiations prove to be significant challenges to genome stability, due to 
their ability to induce a range of different types of DNA damage and because 
these have distinct spatial patterns due to the type of radiation exposure. 
  
IR induced DNA damage includes single DNA strand breaks (SSBs), double 
DNA strand breaks (DSBs) and base modifications such as oxidation, 
alkylation, deamination, loss of bases residues to produce apurinic or 
apyrmidinic sites (AP sites), all of which can indirectly lead to SSBs and/ or 
DSBs. There are also crosslinks formed involving DNA-DNA and DNA-protein 
interactions (see figure 1).  
The most critical of these lesions in terms of lethality and mutation probability is 
the DSB, which is considered to be a form of “complex DNA damage” also 
termed clustered damage or multiply damaged sites (132). Complex DNA 
damage is usually described as two or more lesions within one to two helical 
turns of the DNA arising from a single radiation track and distinct from 
endogeneous DNA damage (46). IR causes DNA lesions by direct interaction 
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with DNA or indirectly via the generation of reactive species.  In the case of X-
rays, most DNA damage induced occurs via the latter method. Studies of DSB 
induction in mammalian cells exposed to X-rays suggest that ~70% of the total 
DSBs result indirectly by interaction of reactive oxygen, such as hydroxyl 
radicals, that are generated by the ionisation of other molecules, such as water, 
in close proximity to the DNA. In contrast, heavy ions have a higher probability 
of a particle traversal directly causing a DSB and therefore rely less on radical 
species for DNA damage induction. 
This review will cover key aspects of the induction, sensing and repair of DSBs 
caused by IR. Aside from the aspects of complex damage, most of the sections 
covered are of relevance to other agents that induce DSB directly or indirectly. 
 
2. Sensing DNA double strand breaks  
In order for the DSB repair mechanisms (described in section 3) to be 
successfully carried out, the DNA damage needs to be detected, cell cycle 
arrest must be induced and the lesion can then be repaired. This process is 
known as the DNA damage response (DDR), which involves interplay between 
three distinct sets of proteins as proposed by Jackson et al. (57). Damage is 
initially detected by sensor proteins, which recognise sites of damage within the 
DNA. These sensor proteins are recruited to damaged sites and amplify the 
damage signal to a set of proteins known as transducers which function to 
relay the signal to downstream effector proteins (12) (see figure 2). It is the 
activated effector proteins which then function to induce cell cycle arrest, DNA 
damage repair or apoptosis (57).  
Despite the method ultimately used to repair the damage (HR or NHEJ), DSBs 
are initially sensed by the Mre11-Rad50-Nbs1 (MRN) complex. This highly 
conserved complex also has a role in the processing and repair of DSBs (see 
section 3) (123). Each of the proteins within this complex has different functions 
in DNA damage signalling. Mre-11 is a 70-90 kDa protein which possesses 
DNA binding activity and appears to function to recruit other DNA repair 
proteins to the site of DNA damage. It also has DNA endonuclease and 
exonuclease activity (25). Rad50 is a 150 kDa protein that directly interacts 
with Mre11 (59) and functions to partially unwind double stranded DNA termini, 
enabling other proteins to access the site of damage and carry out repair 
functions. Finally, Nbs1 is a 65-85 kDa protein that binds to phosphorylated 
proteins via its N-terminus, thereby allowing the recruitment of various DNA 
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damage repair and checkpoint control proteins to the site of DNA damage. 
Therefore, this complex functions both to detect damage and control 
checkpoint signalling in both HR and NHEJ repair pathways. Recent studies 
have indicated that MRN may be recruited to DNA DSBs by the single stranded 
binding protein hSSB1 that has a high affinity for short regions of ssDNA at 
broken DSB ends (101). Recruitment of hSSB1 to IR induced DSBs precedes 
MRN recruitment and, through a direct interaction with Nbs1, hSSB1 mediates 
MRN recruitment to DSB sites (102, 103).  
 
Following DNA damage recognition by the MRN complex, activation of a series 
of transducer and effector proteins occurs to form the DDR. ATM (Ataxia 
telangiectasia mutated), another primary sensor of DNA double strand breaks, 
is recruited to sites of DNA damage by the MRN complex, inducing the 
autophosphorylation of ATM at ser 1981 and its activation. Deficiency of the 
ATM gene results in the neurodegenerative disorder ataxia telangectasia (AT) 
(108). AT is characterized by neurodegeneration, high risk of cancer and 
hypersensivity to IR, a discovery that lead to the proposal of its key role in 
detection and repair of DNA DSBs. In undamaged cells, ATM exists as inactive 
homodimers and multimers. Phosphorylation of ATM at ser 1981 allows 
dissociation of these into monomers with kinase activity capable of downstream 
signalling (7). ATM can then phosphorylate the histone variant 2AX (H2AX) at 
ser 139 up to ~1 Mb on either side of a DSB to form γH2AX, which forms foci at 
the sites of damage that are visible by fluorescent microscopy (105). H2AX can 
also be phosphorylated by the other PI3-kinase like proteins ATR (ataxia 
telangiectasia and Rad3-related protein), which is primarily activated at stalled 
replication forks (130), and DNA-PK (DNA protein kinase) (90), which is 
required for NHEJ. Phosphorylation of ATM, ATR and H2AX leads to an 
amplification of the DNA damage signal and the recruitment of a large number 
of DNA repair and checkpoint control proteins to the site of DNA damage, 
including Mediator of Damage Checkpoint protein 1 (MDC1) (114,115), p53 
binding protein (53BP1) (131), Breast Cancer Susceptibility protein 1 (BRCA1) 
(21,136), Chk1 (140), Chk2 (2,35) and p53 (18) (see figure 2).  Also recruited 
are members of the Fanconi anemia (FA) family of proteins such as FANCD2 
(118), which co-operate with BRCA1 and BRCA2 in the FA/BRCA DNA repair 
pathway. A core complex of 8 FA proteins is recruited to sites of DNA damage, 
leading to ubiquitation of FANCD2 and recruitment of BRCA2 and RAD51 (65). 
Depending on the proteins recruited, the cell can undergo a number of fates, 
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including cell cycle arrest, DNA repair via HR or NHEJ, apoptosis if the damage 
cannot be repaired, or senescence (96).  
 
Recruitment of the MRN complex, phosphorylation of ATM and the subsequent 
phosphorylation of H2AX occur within minutes of DNA DSBs being induced. 
The localisation of the MRN complex to sites of DNA damage has been shown 
to be upstream of ATM phosphorylation and localisation, as silencing of MRN 
proteins results in impaired ATM signalling (19,122). However, the interactions 
between ATM and the MRN complex are not fully understood, as MRN seems 
to be required for the recruitment and activation of ATM, but ATM also appears 
to phosphorylate members of the MRN complex, allowing further downstream 
signalling (122). Recruitment of ATM may be through an interaction of its 
phosphatidylinositol 3-kinase (PI3-K) domain with the C-terminal of Nbs1 (34). 
ATM is not only activated in response to IR induced DNA DSBs. Conditions 
that alter chromatin structure such as exposure to topoisomerases also initiate 
ATM autophosphorylation, however, under these conditions many of the key 
DDR substrates of ATM (such as H2AX, MDC1, SMC1) are not phosphorylated 
indicating that amplification of the DNA damage signal cascade by ATM 
through its downstream effectors requires recruitment of ATM to DSB sites 
(68).  
Some studies suggest that ATM may be targeted to sites of DSBs by the 
monoubiquitination of H2AX by the BMI1/RNF2/RING1 E3 ligase complex 
(135). H2AX is then further di- or polyubiquitinated by RNF8 thus allowing 
recruitment of the BRCA1/RAP80 complex, which is required for DNA repair. 
ATM also stabilises hSSB1 by phosphorylation at theronine 117 in response to 
IR (101). 
 
3. DNA double strand break repair mechanisms 
DNA DSBs consist of two SSBs within one helical turn on opposing strands of 
DNA. IR induced DNA DSBs are not usually simple lesions but rather contain 
multiple complex lesions and overhanging ends (or ragged ends) of DNA that 
cannot be ligated directly and therefore must be removed before repair can 
begin. 
DSBs are primarily repaired by one of two pathways, homologous 
recombination (HR) or non-homologous end joining (NHEJ), irrespective of 
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their cause (see sections 4 and 5). Although the reasons why one repair 
pathway may be chosen over the other are not fully understood, the choice is 
thought to depend on the phase of the cell cycle, the presence of an intact 
sister chromatid, cell type (110), chromatin complexity (45) and the complexity 
of damage induced (87) (see section 4).  
HR requires the presence of an intact sister chromatid as a template and thus 
this pathway is only available during late S and G2 phases (53). Therefore 
during G1 (and early S-phase) when this option is not available DNA DSBs are 
repaired by NHEJ. Although HR is considered to be relatively error free DNA 
repair method, even in the presence of a homologous chromatid, repair factors 
of each pathway compete for binding to DNA DSBs. 
 
a. Homologous recombination repair of IR induced DNA DSBs  
The major event that determines the decision for repair by HR is DNA end 
resection. A crucial event therefore is binding and activity of the MRN complex 
that was described in section 2. The MRN complex binds to DNA at the site of 
a lesion, recruiting and activating ATM (1, 28, 7).  The endonuclease activity of 
Mre11 then facilitates 5’-3’ resection to produce 3’ single stranded DNA ends 
(58, 138). This endonuclease activity is regulated by an interaction with the 
CtBP-interacting protein (CtIP) in an ATM and BRCA1 dependent manner 
(107).  
 
Following the formation of long tails of 3’ ssDNA regions hSSB1 molecules are 
initially bound then displaced by replication protein A (RPA) to begin the 
formation of nucleoprotein filaments that will eventually invade the homologous 
DNA strand of the sister chromatid. A soft X-ray microbeam has been 
employed to show that binding of the hSSB1 protein to resected 3’ ssDNA ends 
not only occurs before RPA binding but is required for the RPA focus 
formation- thus elucidating an early step in the HR pathway (102). RPA is 
activated in response to IR by extensive phosphorylation (66) and plays a 
crucial role in DNA damage checkpoint signalling, control of DNA replication as 
well as each of the main DNA repair mechanisms (143).  
 
The RAD52/BRCA2/RAD51/RAD54 complex is then recruited to the ssDNA by 
a BRCA1/PALB2 (partner and localiser of BRCA2) complex. This facilitates the 
replacement of RPA with RAD51, thus stabilising the filament and catalysing 
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the invasion into the sister chromatid and subsequent Holliday junction 
formation (55, 78). Additionally, direct binding of RAD52 to the ends of DSB 
lesions protects them from exonuclease activity. These vital roles of RAD52 in 
HR may indicate that it plays an important part in the decision for DSB repair by 
HR versus NHEJ (51). RAD51 focus formation can be observed in cells after 
exposure to IR. This focus formation does not occur in cells deficient for 
RAD54, and HR in these cells is less efficient (32). 
 
To facilitate invasion into the sister chromatid strand, the two chromatids are 
tethered together by the structural maintenance of chromosomes proteins 
(SMC) 1, 3, 5 and 6 (also called cohesins) (40). Following invasion to the sister 
chromatid, the two strands are aligned with homologous regions within the 
sister chromatid. DNA synthesis, catalysed by DNA polymerase δ, occurs from 
the 3’ end to replace the sequence of DNA disrupted by the break. Once this 
DNA replication is complete the Holliday junction is resolved by DNA 
resolvases through a complex process that remains unclear (56). Finally, the 
DNA ends are ligated (55). 
 
b. Non-homologous end joining repair 
In late S and G2 phase HR competes with NHEJ and in G1 cells the latter, a 
relatively more error prone process, dominates. The key factors involved in 
NHEJ are the Ku70/Ku80 heterodimer (Ku), the catalytic subunit of DNA-
dependent protein kinase (DNA-PKcs), the nuclease Artemis, XRCC4, DNA 
ligase IV and XRCC4-like factor (XLF). As IR induced DNA DSBs frequently 
contain overhangs and often have phosphate or phosphoglycolate groups 
bound to their 3’ ends, these require processing by additional factors such as 
the DNA polymerases μ and λ, polynucleotide kinase/phosphatase (PNKP) and 
Werner’s syndrome helicase (WRN) before ligation can take place (76). The 
processing of these unligatable ends may result in base loss from either strand 
and is likely to be the reason that that NHEJ is error-prone. For a 
comprehensive discussion of protein and DNA interactions involved in NHEJ 
see (76, 94). 
The first step in this pathway is the rapid recruitment of Ku to IR induced DNA 
DSBs (127) which occurs within a few seconds of irradiation (67). Ku70 and 
Ku80 together form a DNA binding core that has a high affinity for DNA without 
sequence specificity. This may explain the almost instantaneous recruitment of 
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this complex to break sites. Shortly after recruitment to break sites Ku 
translocates along the DNA leaving the ends accessible for processing. Binding 
of Ku results in conformational changes in the C-terminal regions of both Ku70 
and Ku80. This further acts to recruit the other key NHEJ players to sites of 
DSBs. Two DNA-PKcs molecules are recruited to each DNA DSB via an 
interaction with the C-terminal region of Ku80 (111). These two molecules 
tether the DNA ends together and that interaction stimulates their kinase 
activity. This interaction of two DNA-PKcs molecules tethering the extreme 
ends of the broken DNA is often referred to as the “synaptic complex” (27). 
DNA-PK is then phosphorylated at more than 16 sites via autophosphorylation 
and potentially by other kinases such as ATM and ATR. The protein kinase 
activity of DNA-PKcs that is ‘switched on’ by its interaction with DNA and Ku is 
thought to be a necessary step in NHEJ repair. Autophosphorylation of the ser 
2023–2056 PQR cluster and the thr 2609–2647 ABCDE cluster of DNA-PKcs is 
required for repair of IR induced DNA DSBs (20). There is also cross-over at 
this point between the NHEJ and HR pathways. Deficiency of DNA-PKcs 
results in high radio sensitivity (81). Cells in which DNA-PKcs was mutated so 
that key autophosphorylation events were inhibited had reduced capacity to 
undergo HR and were more radiosensitive (4). Therefore the kinase function of 
DNA-PKcs has a criticial role in repair of IR induced DNA DSBs. That function 
is believed to be important for its release from DNA DSBs and laser micro-
irradiation studies have shown that when DNA-PKcs lacked this function it was 
retained longer at the sites of DNA damage (120). 
 
Once DNA ends have been secured they require processing to remove ragged 
ends. The specific enzymes that carry out this processing depend on the 
complexity of the breaks, whether gaps in the DNA need to be filled and what 
groups are blocking the ends of the DNA. The exact timing of DNA end 
processing in NHEJ and the order of recruitment of many factors remains 
unclear but the most likely key players in this stage of NHEJ are summarised 
next. 
 
The nuclease Artemis has 5’-3’ exonuclease activity and acquires 
endonuclease activity in the presence of DNA-PKcs and adenosine 
triphosphate (ATP). The inactivation of the enzyme Artemis causes radiation-
sensitive severe immunodeficiency indicating that it must have a role in repair 
of radiation induced DNA damage. However, cells lacking Artemis still have 
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some DSB repair suggesting that it is only required for the repair of a subset of 
breaks (see section 5 for more on this). One proposed mechanism of 
recruitment of Artemis during NHEJ is by an interaction with DNA-PKcs. Proper 
function of Artemis in NHEJ requires the activation of its endonuclease 
function. Exactly how this occurs remains unclear however, in vitro Artemis has 
been shown to be a phosphorylation target of both DNA-PKcs and ATM. 
Artemis has a role in the processing of IR induced DNA DSBs with DNA hairpin 
loops, 3’-phosphoglycolate groups and functions in the repair of complex 
lesions in an ATM dependent manner (76). 
 
Polynucleotide kinase (PNK) is phosphorylated in response to IR although the 
kinase responsible is unknown (79). Knock down of PNK results in increased 
IR sensitivity, most likely due to defective NHEJ DSB repair (62). PNK is 
involved in the removal of non-ligatable ends at the termini of DSBs. It’s DNA 
phosphatase and DNA kinase activities are key to this function. PNK may be 
recruited to DNA DSBs by an interaction with phosphorylated XRCC4. DNA 
polymerases μ and λ are recruited to sites of IR induced DSBs by their 
interaction with Ku (and possibly XRCC4-DNA ligase IV) and are required to fill 
gaps in the DNA created during the removal of ragged DNA ends. Their 
function in NHEJ is thought to be mainly through their respective BRCA1 C-
terminus (BRCT) domains. DNA pol λ is phosphorylated in response to IR (79). 
Which DNA pol is required depends largely on whether a DNA template is 
required. While DNA pol λ normally requires a template to fill gaps, DNA pol μ 
can direct template-independent-synthesis across a DSB with no terminal 
microhomology (86). Loss even of both these polymerases does not confer 
significantly increased sensitivity to IR, therefore it seems that they are required 
for the repair of only a small subset of IR induced DSBs (92). 
 
Aprataxin and PNK like factor (APLF) also has both exonuclease and 
endonuclease activity, is phosphorylated by ATM, interacts with Ku and its 
downregulation results in defective DSB repair. These findings together 
suggest a role for APLF in NHEJ repair. There is also evidence that The 
Werner’s Syndrome protein (WRN) may have a role in NHEJ. WRN is a RecQ 
helicase that has a number of functions that would be useful in processing non-
ligatable DNA ends. These include 3’-5’ exonuclease, 3’-5’ DNA helicase, 
strand annealing and DNA-dependent ATPase activities. Its exonuclease 
activity is stimulated by its interactions with Ku and the XRCC4-DNA ligase IV 
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complexes. Finally, loss of WRN activity in vivo is associated with cancer 
predisposition, premature aging and genomic instability thus suggesting a role 
in DNA damage repair. 
 
In order to complete the repair of DNA DSBs the processed ends must be 
ligated. In NHEJ this is done by the XRCC4-DNA ligase IV-complex. Although 
XRCC4 is required for NHEJ it has no enzymatic function on its own but 
instead acts as a scaffold bringing other factors to sites of DSBs (61). XRCC4 
has a α-helical region that interacts with a linker region between the two C-
terminal BRCT domains of DNA ligase IV (48). This forms a very stable 
complex that stabilises the activity of DNA ligase IV and via the interaction of 
XRCC4 with Ku brings it close to DNA ends requiring ligation (47). It has been 
proposed that in response to DNA DSBs, XRCC4 is phosphorylated by DNA-
PKcs and that this stabilises the complexes position at the break site and 
promotes ligation. Ligation however, is not dependent on that phosphorylation. 
The nuclear localisation of XRCC4 and its role in DSB repair is also dependent 
on its SUMO-ylation. Further to DNA end ligation by the XRCC4-DNA ligase IV 
complex, XLF is also required for a subset of DNA lesions where the processed 
ends are incompatible. The recruitment of XLF to DNA ends is independent of, 
but is stabilised by the XRCC4-DNA ligase IV complex. 
 
c. Alternate-Non-homologous-end-joining 
An alternative end-joining pathway may be employed when some parts of the 
NHEJ pathway are missing or mutated. There is cross over between this 
pathway and some components of HR and SSB repair (80) pathway is able to 
ligate broken DNA ends in the absence of DNA-PKcs, XRCC4 and DNA ligase 
IV. Instead this pathway may employ PARP1, XRCC1 and DNA ligase III (128). 
In this case PARP1 may bind the DNA DSB and stimulate fusion. The 
XRCC1/ligase III complex then ligates the DNA ends. When Ku is present it 
blocks the access of PARP1 to DSBs. Thus alternative end-joining only occurs 
in NHEJ-deficient cells (129). 
 
4. Choice of repair pathway 
Following IR induced DNA DSB induction, in cells in G1 or S/G2 phase there is 
competition for binding to the lesion by Ku and the MRN complex. The outcome 
of that competition in S-phase dictates the DNA damage repair pathway. 
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Binding of MRN and its activation and recruitment of ATM commits cells to 
repair by HR, whereas successful binding of Ku70-Ku80 takes repair down the 
NHEJ route. Localisation of the MRN complex at DSBs is independent of the 
cell cycle phase (94). A further interaction that may dictate the choice of repair 
pathway in late S-phase is that of 53BP1 and BRCA1. 53BP1 binds DNA near 
sites of DSBs and 53BP1 focus formation can be observed by fluorescence 
microscopy after IR exposure. It may have a role in inhibiting end resection by 
binding to dimethyl-histone H4 Lys20 and tethering DNA ends to facilitate 
ligation. The prevention of DNA end resection by 53BP1 indicates that 53BP1 
binding may favour repair by NHEJ. Conversely, it is thought that BRCA1 can 
counteract the action of 53BP1 but the mechanism is unclear (13). 
There is increasing evidence that DSB repair rate and choice of repair 
mechanism are dependent on chromatin complexity. DSBs that are repaired 
slowly may be in regions of heterochromatin that require prolonged chromatin 
relaxation for repair intermediates to access break sites. It has been shown 
experimentally that sustained activation and localisation of ATM at these break 
sites is crucial for this and that ATM functions in this process to activate KRAB-
associated protein (KAP-1).  pKAP-1 forms persistent foci that co-localise with 
γ-H2AX and these are thought to represent DSBs in heterochromatin. The 
same study also suggested that DSBs in regions of heterochromatin are 
repaired in G2 phase by an Artemis dependent HR pathway. In contrast most 
DSBs in euchromatic regions were repaired during G2 by NHEJ (142, 45). 
 
5. DSB and radiation quality  
a. Complex lesions 
The type of DNA lesions that result from cellular exposure to IR is 
heterogeneous and in general the complexity of breaks strongly depends on 
the characteristics of the incident radiation. The term “radiation quality” is 
commonly used to discriminate the density of ionisations produced along the 
path of a charged particles track as this is correlated with the density of DNA 
lesions caused. Linear energy transfer (LET) is the amount of energy per unit 
distance that is transferred by a particle to the surrounding medium along its 
trajectory. This factor depends on the charge and kinetic energy of the 
particle and is normally reported in units of keV/μm. In first approximation, the 
LET is inversely proportional to the square of the particle kinetic energy, 
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proportional to the square of the particle charge and independent from its 
mass as indicated by the Bethe-Block formula (9);  
    
v = velocity of the particle 
c = speed of light 
β = v/c 
E = energy of the particle 
x = distance travelled by the particle  
Z = particle charge 
e = charge of the electron 
merest = mass of the electron 
n = electron density of the target 
I = mean excitation potential of the target 
ε0 = vacuum permittivity  
 
Although LET is a quantity defined for charged particles, an LET value can 
also be calculated for X-rays leading to an average value of 2 keV/μm for 250 
kVp X-rays. LET is therefore an indication of the ionization pattern (i.e. track 
structure) produced by a particle beam at a certain energy (141). The pattern 
of DNA damage caused by a particle traversal is directly related to the LET 
and track structure of the particle beam. As the primary charged particle 
traverses a cell it causes ionisations itself that are capable of causing DNA 
DSBs due to their spatial and temporal proximity. These ionisations generate 
secondary delta electrons that have tracks away from the trajectory of the 
primary particle. The delta electrons are able to cause further ionisations. The 
result is a penumbra around the primary particle path the width of which 
increases with increasing energy of the primary particle. As charged particles 
slow down (lose energy) the track length of the delta electrons also 
decreases so the pattern of ionisations has a higher density (and LET) near 
the end of the primary particles’ path. This corresponds with the peak of 
energy deposition for charged particles known as the ‘Bragg peak’.  
For charged particles, particularly heavy ions, the probability of causing 
complex, or ‘clustered’ DNA damage increases as LET increases and 
therefore as a given particle slows down. Complex DNA damage caused by 
high LET radiation is believed to be more difficult for the cell to repair and 
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therefore more lethal. An excess of small DNA fragments (<3 Mb) have been 
observed using pulsed field gel electrophoresis (PFGE) of DNA after 
irradiation of human fibroblasts with charged particles of different LET (80-
300 keV/μm). This was not observed after low LET irradiation. These small 
fragments may be created as a result of intra-track ionisations (112). 
 
A DSB is a type of clustered lesion as these breaks are usually formed from 
two DNA lesions on opposite strands within 10 base pairs of each other. 
However ‘complex’ DNA DSBs can also involve two or more breaks on each 
DNA strand within 10 base pairs (23). DSBs induced by high LET ions are 
~70% complex DSBs and 30% simple DSBs, compared to low LET particles 
such as X-rays that cause only 30% complex DSBs. Clustered lesions also 
include non-DSB damage and are most likely made up of closely opposed 
SSBs and abasic damage sites (49). These complex lesions, that potentially 
occur at 4-8 fold higher yields than prompt DSB, are also less repairable than 
single lesions and can lead to a DSB during repair (30). Complex damages 
present a harder challenge for the cellular repair processes due to clustering 
of lesions and the loss of DNA fragments. Clustered DNA lesions are more 
likely to be misrepaired or unrepaired conferring an increased probability of 
chromosome aberrations, mutation and cell death for high LET radiation (5). 
The main methods for studying induction and repair of DNA DSBs in 
radiobiology are PFGE and inspection of ionising-radiation-induced foci (IRIF) 
(see figure 4a and b). Although historically the PFGE method has been used 
most frequently, IRIF based assays provide higher sensitivity thus enabling 
their use at radio-biologically relevant doses (<2 Gy) and are a versatile 
platform for the study of DNA repair factor dynamics. The induction and 
resolution of IRIF has been employed for the investigation of the role of many 
factors involved in the sensing and repair of DNA DSBs, including but not 
restricted to pATM, 53BP1, BRCA1, γH2AX, MRN, RAD51 and DNA-PKcs 
(see figure 4.c for a schematic representation of IRIF resolution over time 
post IR exposure). With the advent of GFP (green fluorescent protein) and 
other live cell tags, it is now also possible to qualitatively and quantitatively 
monitor the DNA repair process in live cells and assess protein interaction 
and turnover at site of damage using techniques such as FRET (Forster 
Resonance Energy Transfer) and FRAP (Fluorescent Recovery After 
Photobleaching). The effectiveness of heavy charged particles for the 
induction of complex DNA DSBs has been shown using both methods (94, 6, 
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121). Imaging of IRIF has also shown that very early (< 1 hr) after irradiation 
with high LET radiation, foci are larger and more intensely fluorescing 
compared to those resulting from X-irradiation (22). IRIF localise in stripes 
through cell nuclei along heavy ion tracks and the co-localisation of DNA 
repair factors involved in multiple repair processes suggests the highly 
complex nature of the lesions induced (86, 5). These complex lesions may 
include multiple DSBs, SSBs and abasic sites within close proximity that 
appear as a single larger and brighter focus but are repaired slower than 
those observed following low LET exposures (23). 
 
b. Mechanism for repair of high LET complex DSBs 
Repair kinetics studies have identified two specific components: a fast one 
which is responsible for the majority of the repair and which dominates the 
repair response in the immediate hours post-irradiation, and a slower 
component which protracts for 24 hrs and longer. It has also been shown that 
the slow phase of DNA repair is longer for high LET induced DNA DSBs than 
for low LET DSB. This is most likely due to a higher frequency of complex 
clustered damage that require additional processing before DNA ligation can 
occur and due to the presence of unrepairable lesions. Analysis of DNA 
rejoining by PFGE demonstrated an LET dependent increase in rejoining time 
up to ~200 keV/μm (105, 133). Studies of IRIF resolution kinetics has 
provided further evidence for the complex nature of high LET particle induced 
lesions. The disappearance of heavy ion induced foci is slower compared to 
X-rays, and heavy ion (such as 1 GeV/nucleon Iron ion) exposures induce a 
proportion of foci that persist even beyond 48 hours after exposure (87, 6, 
121). These persistent foci are generally believed to represent unrepaired 
DSBs, however, these have also been associated with IR induced 
senescence and chromatin alterations (116, 115).  
Precisely how high LET DNA DSB processing differs from that of simple 
DSBs is yet to be elucidated. The kinase ATM and nuclease Artemis have 
been associated with the repair of complex DNA DSBs (99, 72). Recent 
evidence suggests that complex clustered DNA damages that include DSBs 
with other DNA lesions close to them are processed in the slow phase of 
repair by a sub-pathway of NHEJ that is dependent on ATM, DNA-PKcs and 
Ku (98). That study showed that simple DSBs (induced by ultra soft X-rays) 
are repaired by an NHEJ pathway that does not require ATM or DNA-PKcs, in 
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contrast those factors were necessary for repair of more complex lesions 
(induced by multi photon near-infrared microbeam). This is probably due to a 
necessity for extensive DSB end processing in these complex lesions. Finally, 
evidence suggests that slow kinetics of repair of high LET radiation lesions 
may be strongly influenced by chromatin complexity. Proposed methods for 
dealing with heterochromatic DSBs are described in section 3. 
 
6. DSB and replicative stress  
a. Oxidative stress induced DSB 
DNA DSBs arise following direct damage to DNA by IR. However, other 
mechanisms involving oxidative stress can also lead indirectly to DSB induction 
(see figure 5). Reactive oxygen species (ROS) can be produced in cells as a 
consequence of various cellular processes, including CO2 metabolism, 
stimulation of immune responses or release of cytokines and chemokines from 
neighbouring cells. ROS can have a number of different effects on 
carbohydrates, proteins, lipids and DNA (70), including causing the oxidation of 
purines and pyrimidines, AP DNA sites and SSBs. The majority of this damage 
is repaired using base excision repair (BER) or nucleotide excision repair 
(NER). BER is important for the removal of non-bulky modifications and abasic 
sites and involves removal of a damaged base by a DNA glycosylase, incision 
at the remaining site, addition of an undamaged base by DNA polymerase and 
finally re-ligation of the DNA by a DNA ligase. NER is important in repair of 
bulky base modifications which cause distortion of the DNA helix and requires 
the damage to be recognised by xeroderma pigmentosum (XP)/cockayne 
syndrome (CS) proteins, DNA unwinding and incision, addition of an 
undamaged base and ligation. However, it is estimated that approximately 1% 
of these single strand lesions are converted into DSBs (118), particularly at 
replication forks during DNA replication. Recognition of these DSBs differ from 
DSBs induced by direct IR in that ATR appears to play an important role, as 
well as ATM. They are then consequently repaired by NHEJ or HR.  
b) Hypoxia 
Relative oxygen concentrations within cells have also been reported to 
influence both levels of DNA damage induced and how this damage is 
repaired. Hypoxia within tumours has been associated with increased 
radioresistance and decreased disease-free survival (126). DNA repair 
pathways including HR and NHEJ have been shown to be less effective in 
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hypoxic conditions (89). This is thought to be due to the alteration of expression 
of DNA DSB-associated genes (reviewed by (14)). Cellular responses to 
hypoxia are mediated primarily by the HIF (hypoxia inducible factor) family of 
transcription factors. DNA DSB repair proteins downregulated in response to 
hypoxia include BRCA1 (10), RAD51, RAD52 and BRCA2 (82). The result of 
this is that DNA DSB repair by HR is compromised in hypoxic conditions, 
potentially leading to an increase in biological effects including translocations or 
chromosomal deletions.  
Oxidative stress may also positively or negatively impact on DNA damage 
recognition and repair. ATM has been shown to be activated by oxidation in the 
absence of either a DSB or MRN recruitment indicating that it may be a key 
mediator in the cellular response to oxidative stress (50), while DNA-PKcs 
which stabilises pP53, has been shown to be negatively regulated by Artemis 
during oxidative stress therefore preventing G1 arrest and apoptosis (139). 
Furthermore, repair of DSBs by NHEJ under conditions of oxidative stress is 
impeded due to an inability of Ku to bind to the lesion. This may be due to an 
oxidation mediated conformational change of Ku (8). 
 
 
c. Bystander effects 
DNA DSBs can also result following signalling from neighbouring cells that 
have been damaged by radiation. The radiation-induced bystander effect is 
defined as the ability of an untreated cell to respond to signals from a 
neighbouring irradiated cell (96). Bystander effects have been observed in a 
wide range of cell lines and in vivo (96). The damage can arise in two ways, 
either through intercellular communication via gap junctions, or via the release 
of soluble factors, which can travel to distant cells. The soluble factors released 
are dependent on the cell type which has been irradiated, but have been 
reported to include chemokines/cytokines (29, 91, 109), death ligands (74), 
ROS (75), nitric oxide (75, 109), growth factors (29) and Ca2+ (75). Bystander 
effects are reported to be the result of increased ROS generation in non-
irradiated cells as a consequence of signalling from irradiated cells, most likely 
due to increases in intracellular Ca2+ and subsequent mitochondrial 
depolarisation and ROS release (75). Endpoints for which bystander effects 
have been observed include DNA damage, mutations, terminal differentiation 
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and apoptosis (reviewed by Prise and O’Sullivan (96)). DNA damage occurring 
in cells following bystander signalling differ from the responses of directly 
irradiated cells, with damage being detected at later timepoints. Bystander-
induced DNA damage is also primarily detected by ATR, with ATM found to act 
downstream of ATR in bystander cells (see figure 5) (16, 96).  
 
7. Targeting DSB repair in cancer therapy 
The aim of radiation therapy is to induce DNA damage in the form of DSBs, 
which ultimately leads to cell death within the tumour. However, resistance is a 
major mechanism limiting the effectiveness of radiotherapy as a cancer 
treatment. One way in which tumour cells can develop resistance to radiation 
treatment is by improving the effectiveness of DNA repair pathways, thereby 
enabling the cells to repair the damage and allowing the cells to survive and 
replicate. Targeting these repair pathways may therefore be a good therapeutic 
option to try to improve the effectiveness of radiation treatment.  
 
a.  Expression of DNA damage repair proteins in cancer 
AT is a condition resulting from mutation of the ATM gene. It is characterised 
by a predisposition to cancer and very high cellular sensitivity to radiation 
treatment. As explained in sections 2 and 3, ATM plays a role early in the DNA 
damage response network, being one of the first proteins to be phosphorylated 
following DNA damage detection. It is therefore easy to see why loss of 
function of ATM can lead to an increased predisposition to cancer 
development, as loss of ATM has a major impact on the cells ability to repair 
damage efficiently. Mutations in ATM lead to a much higher risk of 
development of breast cancer (98, 119) and leukemia (77), while also reducing 
time to recurrence. Mutation of ATM has also been reported to lead to an 
increased sensitivity to radiotherapy treatment (17), indicating that this protein 
may be important in radiation response.  
 
Altered expression of other proteins in DNA repair pathways have been shown 
to both increase risks of developing cancer and influence the effectiveness of 
treatments designed to induce DNA damage. For example, overexpression of 
members of the FA family of proteins, which function to co-operate with BRCA1 
and BRCA2 in DNA damage repair by HR, leads to a higher risk of developing 
various types of cancer, including breast cancer (31, 41, 97, 112, 124), 
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leukemia (33, 54) and pancreatic cancer (24, 52, 60). In addition, low 
expression of FA proteins have been shown to predict response, with low 
FANCD2 expression associated with increased response of esophageal cancer 
patients to treatment with a combination of chemotherapy and radiotherapy (3). 
It is also widely known that mutations of the DNA damage repair proteins 
BRCA1 and BRCA2 significantly predisposes carriers to development of breast 
and ovarian cancer, with up to 85% of these tumours associated with changes 
in expression levels of BRCA1 or BRCA2 (39). BRCA status may also be 
important in patient outcome, with BRCA2 mutations reported to correlate with 
improved survival and chemotherapy response in ovarian cancer patients 
(137). PARP, which is important for detecting single strand DNA breaks, plays 
a key role in the response of HR defective cells to DNA damage, as unrepaired 
SSBs can be converted to DSBs which the cells cannot effectively repair. 
PARP is overexpressed in breast cancer compared to normal breast tissue, 
and its overexpression has also been correlated with high grade, tumour size 
and worse survival (44). These studies highlight the importance of DNA repair 
pathways in cancer treatment outcomes and the need to target these pathways 
in order to improve response rates.  
 
b. Therapeutic inhibition of DNA repair pathways 
Various inhibitors have been developed to target DNA repair proteins. A dual 
PI3K/mTOR inhibitor, NVP-BEZ235, has been reported to potently inhibit both 
ATM and DNA-PKc, thereby inhibiting both HR and NHEJ pathways. This 
inhibitor has shown promising results, showing significant radiosensitisation in 
a panel of cell lines and in tumour xenograft models (85). In addition, this 
inhibitor is currently in Phase1/2 clinical trials for the treatment of solid tumours. 
Inhibition of ATM using different inhibitors has also shown to significantly 
increase sensitivity to radiation treatment (reviewed by (71)). Interestingly, the 
inhibition of ATR function in hypoxic cells, which show higher levels of radiation 
resistance, using the specific inhibitor VE-821 has been shown to sensitise 
these cells to radiation treatment, indicating that this approach may be 
important in a therapeutic setting for the treatment of tumours with hypoxic 
regions (93).  
 
Chk1/Chk2 inhibitors have also been tested in combination with DNA damaging 
agents. The inhibitor AZD7762 has been used in pancreatic cancer cells both 
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in vitro and in tumour xenograft models and has shown to be effective at 
inducing cell death and tumour regression both as a single agent and in 
combination with gemcitabine and radiation (84). Mitchell et al. have also 
shown that AZD7762 can sensitise a panel of human tumour cell lines to 
radiation treatment, and in addition can sensitise HT29 xenograft models to 
radiation with minimal side effects from treatment with the inhibitor both alone 
and in combination with radiation (83), indicating the potential of this inhibitor 
as a clinical agent. Other Chk inhibitors have also been shown to increase 
radiosensitivity of tumour cells, such as XL-844 (104) and PF-477736 (37), 
which has shown potential both as a single agent and in combination with DNA 
damaging agents (11).  
 
c. Synthetic lethality 
Many types of cancer arise from cells that have developed mutations in DNA 
DSB repair pathways. Alterations in these pathways allow cells to accumulate 
damage and other mutations but still retain their ability to divide. However, cells 
possess numerous DNA repair pathways, which can be activated following 
DNA damage. If one of these pathways is inactivated in tumour cells due to 
mutations of key proteins within the pathway, the tumour cells can become 
more dependent on other repair pathways to repair replication-associated and 
other types of DNA damage. This opens up important therapeutic options, as 
targeting the intact pathways should prevent the tumour cells from repairing 
any DNA damage incurred and allow the cells to undergo apoptosis. This 
concept has been named synthetic lethality (see figure 6).  
 
Synthetic lethal interactions can be seen between a number of proteins, most 
notably in the use of PARP inhibitors in a BRCA mutant setting (36). Cells that 
have developed a mutation in BRCA1 or BRCA2 have defective HR function. 
Inhibition of PARP results in an accumulation of SSBs, which can be converted 
into DNA DSBs at replication forks. These DSBs cannot be repaired in HR 
deficient cells, resulting in the cells undergoing apoptosis. PARP inhibitors may 
be very useful in treatment of patients with tumours possessing BRCA 
mutations, as tumour cells have developed mutations in BRCA1 or BRCA2 
while the surrounding normal tissue will not have these mutations. This means 
that the inhibitors should specifically target the tumour cells while sparing the 
Kavanagh et al.   
22  
surrounding normal cells (36), which have an intact HR pathway to repair the 
damage.  
 
Inhibition of PARP has been shown to sensitise cells to radiation treatment 
(125). Importantly, the use of PARP inhibitors or PARP targeted siRNA as a 
single agent has been shown to result in a significant reduction in cell survival 
of BRCA2 mutant cells (15, 36). In addition, xenograft models developed from 
patient tumour samples have shown that PARP inhibitors induce significant 
apoptosis and reduce proliferation of BRCA2 mutant tumours, both as a single 
agent and in combination with DNA damaging agents, while BRCA2 wild-type 
tumours show greatly reduced responses to PARP inhibition (69). These 
studies and others have indicated the importance of PARP inhibitors as a 
treatment strategy, leading to the testing of PARP inhibitors in clinical trials. In 
a Phase I clinical trial, the PARP inhibitor olaparib was shown to exhibit 
antitumour activity in patients with BRCA1 or BRCA2 mutations while causing 
few adverse side effects (38). This inhibitor was also tested in Phase II clinical 
trials. Gelmon et al. reported that 41% of BRCA1 or BRCA2 mutant ovarian 
cancer patients showed a response following treatment with olaparib, 
compared to 24% of patients without mutations (43). However, another study 
reported that there was no statistically significant improvement in progression 
free survival in ovarian cancer patients with BRCA1 or BRCA2 mutations 
treated with the inhibitor (63). Astra Zeneca have withdrawn olaparib from 
Phase III trials after analysis of the data indicated that there was no 
improvement on overall survival following treatment of BRCA1 and BRCA2 
mutant ovarian cancer patients. However, it is still being investigated in other 
disease settings, such as BRCA1/2 defective breast cancer. There are also 
other PARP inhibitors in various phases of clinical trials, including iniparib 
(which was the first PARP inhibitor to be tested clinically), rucaparib and 
veliparib.  
 
PARP inhibitors also show synthetic lethality when combined with ATM 
mutations (134), as well as mutations in MRE11 and NBS1 (26). Synthetic 
lethal interactions are also observed between mutations of the FA family 
members and ATM inhibitors (64).  
 
8. Summary  
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DNA double-strand breaks are critical lesions for cells which if not repaired 
can lead to a high probability of mutations and cell death. Taking ionising 
radiations as an example of an effective inducer of DNA DSB, lesion 
complexity, where additional damages are associated with a DSB due to the 
radiation track structure, is also important causing additional challenges for 
repair pathways. DSBs can also be produced indirectly via oxidative stress 
and the consequences of replication fork stalling, typically seen for ionising 
radiation induced bystander responses. Cells have evolved several options 
for sensing and repairing DSBs with the molecular mechanisms being 
defined. The restricted options of repair pathways available to tumour cells, 
when specific mutations in key repair enzymes are present, allows selective 
targeting of these particularly via synthetic lethality approaches. Our 
expanding knowledge of DSB induction, using ionising radiation as a 
paradigm, is providing new opportunities to target these in cancer therapy. 
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List of Abbreviations 
53BP1 p53 binding protein 1 
AP apurinic/apyrmidinic 
APLF aprataxin and PNK like factor 
AT ataxia telangectasia 
ATM ataxia telangectasia mutated 
ATP adenosine triphosphate 
ATR ataxia telangectasia and Rad3-related protein 
BER base excision repair 
BMI1 B lymphoma Mo-MLV insertion region 1 
BRCA breast cancer susceptibility protein 
BRCT BRCA1 C-terminus 
Chk checkpoint kinase 
CO2 carbon dioxide 
CS cockayne syndrome 
CtIP CtBP-interacting protein 
DDR DNA damage response 
DNA  deoxyribonucleic acid 
DNA pol DNA polymerase 
DNA-PK DNA protein kinase 
DNA-PKcs catalytic subunit of DNA-PK 
DSB double DNA strand break 
FA/FANC Fanconi anemia 
FRAP fluorescent Recovery after photobleaching 
FRET forster Resonance Energy Transfer 
GeV gigaelectron volt 
GFP green fluorescent protein 
H2AX histone variant 2AX 
HR homologous recombination 
hr hour 
hSSB1 human single stranded DNA binding protein 1 
IR ionizing radiation 
IRIF ionizing radiation induced foci 
kDa kilo dalton 
KAP-1 KRAB-associated protein  
keV kilo electonvolts 
Ku Ku70/Ku80 complex 
kVp kilovoltage peak 
LET linear energy transfer 
Lys lysine 
Mb mega bases 
MDC1 mediator of damage checkpoint protein 1 
MRN Mre11-Rad50-Nbs1 complex 
mTOR mammalian target of rapamycin 
NER nucleotide excision repair 
NHEJ non-homologous end-joining 
PALB2 partner and localiser of BRCA2 
PARP poly ADP ribose polymerase 
PFGE pulsed field gel electrophoresis 
PI3-K phosphatidylinositol 3-kinase 
PNK polynucleotide kinase 
PNKP polynucleotide kinase/phosphatase 
RING1 really interesting new gene 1 
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RNF2 RING finger protein 2 
ROS reactive oxygen species 
RPA Replication protein A 
Ser serine 
siRNA small interfering RNA 
SMC structural maintenance of chromosomes proteins 
SSB single strand DNA break 
ssDNA single stranded DNA  
Thr threonine 
UV ultra violet 
WRN Werner's syndrome helicase 
XLF XRCC4-like factor 
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Figure Legends 
Figure 1. Introduction to radiation induced DNA damage. Ionizing radiation causes 
many different types of damage to DNA, by direct and indirect routes. That damage 
ranges from ‘simple’ lesions such as base or sugar modifications, DNA-protein 
interactions; to DNA crosslinks and single strand breaks to more ‘complex’ lesions 
such as DNA double stand breaks. 
Figure 2. Pathways sensing DNA DSBs. DNA double strand breaks are initially 
recognised by sensor proteins, such as the MRN complex, MDC1 and γH2AX. These 
sensor proteins activate downstream transducer proteins including ATM, ATR and 
53BP1, which function to activate effector proteins, resulting in cell cycle arrest, DNA 
damage repair or cell death pathways, if the damage cannot be repaired.  
Figure 3. DSB repair pathways. DNA double strand breaks are repaired 
predominantly by one of two pathways. 1) Homologous recombination (HR) requires 
a homologous sister chromatid as a template from which to rebuild sections of DNA 
lost at break sites. This method has high fidelity. 2) Non-homologous end-joining 
(NHEJ) repair can be employed in the presence or absence of a sister chromatid. In 
this repair process ragged ends of DNA at sites of lesions are first tethered together 
then processes and any gaps filled before the ends are ligated to complete repair. 
Figure 4. DSB repair and radiation quality. DNA DSBs can be detected by 
immunofluoresence using antibodies to factors recruited to, or modified at breaks 
sites, such as γH2AX. Examples of γH2AX foci induced by low LET radiation such as 
X-rays (a) and high LET radiation such as helium ions (b) are shown. Analysing the 
kinetics of foci disappearance and can indicate the complexity of DNA lesions 
caused by radiations of different quality. A schematic illustrating the difference in foci 
resolution kinetics between high and low LET radiations is shown in (c). 
Figure 5. DSB repair and oxidative stress. DNA double strand breaks can occur as a 
consequence of oxidative stress within the cell or as a downstream effect of 
bystander signaling by chemokines, cytokines or death ligands released from other 
cells. This damage is recognised primarily by ATR, with ATM acting downstream in 
the pathway.  
Figure 6. Synthetic lethality. Cells possess numerous DNA repair pathways. In the 
case of double-strand break repair, these pathways include HR and NHEJ. a) When 
both pathways are intact cells can efficiently repair and DNA damage encountered. If 
Kavanagh et al.   
36  
one of the pathways is lost, cells can rely on the second pathway to repair damage 
and allow the cells to survive. b) Inhibitors targeting one of the pathways (denoted x) 
have little effect on DNA repair and cell survival when the other pathway is intact. 
However, if one of the pathways is mutated, inhibition of the other pathway results in 
the cell being unable to repair damage and cell death.  
 
 
 
 
 





